Date Filed | Type | Description |
01/06/2023 |
4
| Bourdow Carrie L. (President & CEO) has filed a Form 4 on TREVENA INC
Txns:
| Granted 100,000 shares
@ $0 |
|
12/20/2022 |
4
| Bourdow Carrie L. (President & CEO) has filed a Form 4 on TREVENA INC
Txns:
| Paid exercise price by delivering 1,342 shares
@ $1.55, valued at
$2.1k
|
|
12/06/2022 |
4
| Bourdow Carrie L. (President & CEO) has filed a Form 4 on TREVENA INC
Txns:
| Paid exercise price by delivering 3,560 shares
@ $3.42, valued at
$12.2k
|
|
08/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/21/2021 |
4
| Bourdow Carrie L. (President & CEO) has filed a Form 4 on TREVENA INC
Txns:
| Paid exercise price by delivering 33,546 shares
@ $0.7, valued at
$23.5k
|
|
12/08/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/04/2021 |
4
| Bourdow Carrie L. (Director) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Sold 777 shares
@ $1.2, valued at
$932.4 |
|
07/30/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/31/2020 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
12/18/2020 |
4
| Bourdow Carrie L. (President & CEO) has filed a Form 4 on TREVENA INC
Txns:
| Granted 471,100 shares
@ $0 Granted 706,650 options to buy
@ $2.25, valued at
$1.6M
|
|
12/09/2020 |
4
| Bourdow Carrie L. (President & CEO) has filed a Form 4 on TREVENA INC
Txns:
| Paid exercise price by delivering 132,934 shares
@ $2.27, valued at
$301.8k
|
|
07/31/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/08/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/26/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/26/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
12/13/2019 |
4
| Bourdow Carrie L. (President and CEO) has filed a Form 4 on TREVENA INC
Txns:
| Granted 657,000 shares
@ $0 |
|
12/04/2019 |
4
| Bourdow Carrie L. (President and CEO) has filed a Form 4 on TREVENA INC
Txns:
| Paid exercise price by delivering 17,804 shares
@ $0.6889, valued at
$12.3k
|
|
09/20/2019 |
4
| Bourdow Carrie L. (President and CEO) has filed a Form 4 on TREVENA INC
Txns:
| Granted 250,000 options to buy
@ $1, valued at
$250k
|
|
08/01/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/04/2019 |
4
| Bourdow Carrie L. (President and CEO) has filed a Form 4 on TREVENA INC
Txns:
| Paid exercise price by delivering 17,802 shares
@ $1.17, valued at
$20.8k
|
|
02/05/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/07/2018 |
4
| Bourdow Carrie L. (President and CEO) has filed a Form 4 on TREVENA INC
Txns:
| Granted 250,000 shares
@ $0 Granted 250,000 options to buy
@ $0.65, valued at
$162.5k
|
|
10/01/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/04/2018 |
4
| Bourdow Carrie L. (Director) has filed a Form 4 on Nabriva Therapeutics plc
Txns:
| Granted 29,000 options
@ $0 |
|
03/02/2018 |
4
| Bourdow Carrie L. (EVP & COO) has filed a Form 4 on TREVENA INC
Txns:
| Granted 124,000 options to buy
@ $1.79, valued at
$222k
Granted 112,500 options to buy
@ $1.79, valued at
$201.4k
|
|
09/19/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/29/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/02/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/28/2017 |
3/A
| Bourdow Carrie L. (Director) has filed a Form 3/A on Nabriva Therapeutics Plc |
06/27/2017 |
3
| Bourdow Carrie L. (Director) has filed a Form 3 on Nabriva Therapeutics Plc |
|